The primary role of No Deprine (Tofisopam) is to provide support that helps ease the overall symptom burden for heightened emotional states and the related physical distress. The compound is relevant for easing anxiety and is commonly used to help with symptoms of alcohol withdrawal. The medication is generally applied in clinical settings where short-term symptomatic assistance is needed, focusing on managing symptom fluctuations.

It is relevant in contexts marked by increased discomfort or tension, such as addressing psychological tension, restlessness, and the physical symptoms of heightened physiological activity (like palpitations or muscle tension). This supportive approach is often utilized when patients must preserve mental clarity and is generally used in situations where minimizing drowsiness is important. This generally contributes to increased day-to-day comfort during symptomatic periods by providing supportive relief when symptoms interfere with routine activities.

Quick Fact: Support for Nervous System Stress
Symptom Focus	Psychological tension and anxiety-driven somatic (physical) manifestations.
Key Benefit	Symptomatic support that is generally used when preserving alertness is important.
Use Context	Conditions characterized by periods of heightened symptoms requiring short-term assistance.

Eligibility Scope

Category	Eligibility Rule
Populations for whom use is allowed:	Adult patients for whom the medicinal product is indicated.
Populations for whom use is not recommended:	Use in chronic psychosis or obsessive compulsive phobic disorders. Monotherapy for depression or depression associated with anxiety due to the risk of suicide/aggressive behavior.
Populations for whom use is contraindicated:	Individuals with hypersensitivity to the drug or benzodiazepines; patients with decompensated respiratory insufficiency, sleep apnea, coma, or narrow-angle glaucoma. Co-administration with tacrolimus, sirolimus, or cyclosporine is also prohibited.
Age-related eligibility rules:	Adults are the target population. Safety and efficacy have not been established for the paediatric population (under 18 years of age).
Condition-specific eligibility rules (Use with Caution):	Elderly patients, patients with kidney or liver disease, organic disorders of the brain (e.g., atherosclerosis), or epilepsy (due to seizure risk).
Pregnancy and lactation eligibility status:	First trimester of pregnancy: Use is not recommended. Breastfeeding/Lactation: The medicine should not be used.

---

Eligibility Classifications

Classification	Regulatory Status
Eligibility severity classification:	Contraindicated / Not Recommended / Caution / Not Established.
Eligibility-context constraints:	Hypersensitivity, specific psychiatric and respiratory conditions, functional impairment, concurrent CYP3A4 inhibitors, and reproductive status.

---

Resulting Eligibility Structure

Official eligibility statements:

• The medicine is contraindicated in several groups, including those with hypersensitivity to its components or severe, decompensated respiratory failure.
• Use is not recommended in the paediatric population (under 18 years) because safety and efficacy have not been established.
• The drug should not be used during breastfeeding, and is not recommended during the first trimester of pregnancy.
• Special caution is required when using the drug in elderly patients and individuals with liver disease, kidney disease, or epilepsy, as officially documented in regulatory labeling.

Interactions with other medicines and products

Official regulatory information for No Deprine (Tofisopam) identifies drug interactions primarily through its effect on central nervous system (CNS) activity and its metabolic pathway.

Pharmacokinetic Interaction

• Medicinal product categories: Substrates of the Cytochrome P450 3A4 ( CYP3 A4) enzyme system.
• Mechanistic basis: No Deprine is documented as a CYP3 A4 inhibitor. Co-administration with drugs that are cleared by this enzyme may increase the concentration of the co-administered drug in the body.
• Interaction-related restrictions: The co-administration of No Deprine with potent CYP3 A4 substrates, such as certain immunosuppressive agents (e.g., tacrolimus), has been associated with clinically relevant increases in the substrate's plasma levels, necessitating therapeutic modification.

Pharmacodynamic Interactions

• Medicinal product categories: Central Nervous System (CNS) Depressants.
• Specific interacting medicines: CNS depressants, including certain sedatives, hypnotics, opioids, and benzodiazepines (e.g., alprazolam, diazepam), are listed in regulatory documents as interacting agents.
• Interaction-context constraints: The concurrent use of No Deprine with these agents may result in an additive effect on CNS depression.
• Other substances: Alcohol is noted to interact with the medication, and its consumption is advised to be avoided while using this product to prevent enhancement of central nervous system effects.

The regulatory profile highlights two major types of risk: the potential for systemic exposure to CYP3 A4 substrate medicines to rise significantly, and the risk of heightened CNS depressant effects when combined with other agents affecting the brain. Therefore, patients using No Deprine must be monitored for adverse effects when prescribed with CYP3 A4 substrates or other CNS depressants.

Tofisopam's mechanism of action relies on modulating the cell's internal environment rather than directly binding to and activating the inhibitory GABA A receptor complex. This distinct approach is achieved through two complementary actions.

Atypical Modulation via Enzyme Inhibition

The primary action involves the selective inhibition of specific Phosphodiesterase (PDE) enzymes, particularly PDE-4A1 and PDE-10A1, which are crucial for cellular communication in the central nervous system. By blocking these enzymes, the drug prevents the breakdown of key intracellular messengers, cyclic AMP (cAMP) and cyclic GMP (cGMP). This rise in cyclic nucleotide levels modulates the activity of protein kinases, thereby adjusting the firing rate and signal transmission of specific neurons in limbic pathways governing neural arousal.

Downregulation of Sympathetic Outflow

The resulting functional changes in the brain's control centers lead to a functional downregulation of the sympathetic nervous outflow. This central change restricts excessive neural signaling propagating to peripheral systems. Because the drug does not interact with the GABA A receptor's benzodiazepine site, the functional consequence does not include the mechanism responsible for general sedation or muscle relaxation.

How to Use No Deprine: Official Administration Guidelines

This section outlines the specific administration instructions for No Deprine (Tofisopam).

Administration Procedure

Instruction Component	Official Guidance
Route of Administration	The medication is for oral use. Swallow the tablet whole with a glass of water.
Preparation Requirements	Do not crush, break, or chew the tablet.
Timing in Relation to Meals	Can be taken with or without food.

---

Dosing and Schedule

Instruction Component	Official Guidance
Standard Dosing Schedule	For adults, the general dosing is one tablet (50 mg) at a time, three times a day (three daily administrations).
Dosage Adjustment Rule	The dosage may be adjusted according to the patient's age or current symptoms, as directed by a healthcare professional.
Missed Dose Protocol	If a dose is missed, take the missed dose as soon as possible. However, if it is almost time for the next scheduled dose, skip the missed dose and continue the regular schedule. Never take two doses at one time to make up for a missed dose.

---

These official administration guidelines establish a clear, standardized procedure for the drug's use. The instructions mandate a consistent oral route, a maximum quantity of one tablet per administration, and a defined frequency of three times a day. Additionally, the guidelines explicitly address how to manage a missed dose to prevent accidental overdose, ensuring the medicine is used according to the precise protocol.

Evidence for Use in Anxiety and Psychovegetative Symptoms

Short-term Randomized Controlled Trials (RCTs) was observed in adult outpatients with anxiety conditions characterized by fluctuating or episodic manifestations. Research examined how symptoms evolve, comparing the compound against a non-active placebo and another drug being studied. The focus was on outcomes related to systemic or functional imbalance, such as anxiety severity using standardized scales and the assessment of somatic complaints. Research reported patterns related to anxiety symptom severity scores between groups, and described patterns regarding the assessment of outcomes related to physical discomfort. The research landscape has a limited volume of modern, large-scale RCTs, and sample sizes were modest in some foundational studies.

Comparative Evidence and Effects on Cognitive Function

Studies explored the agent alongside both a placebo and another type of tranquilizer agent. Researchers monitored the outcomes reflecting daily functioning or activity level by including measurements of psychomotor and intellectual performance. Findings indicate that measurements of cognitive and psychomotor function was associated with patterns of change that may be different from patterns observed with the comparator agent. Studies reported that measurements in the Tofisopam group was associated with patterns similar to those observed in the placebo group.

Evidence in Acute Alcohol Withdrawal Syndrome

Tofisopam was evaluated in the context of acute management for conditions involving periods of heightened symptoms, specifically mild Alcohol Withdrawal Syndrome (AWS). The research examined outcomes capturing phases of heightened symptom activity, such as measurements of withdrawal severity and vegetative symptoms. Evidence contributes to the broader evidence landscape for short-term symptom changes in this context. However, comparative evidence is lacking for Tofisopam directly against other standard agents used for alcohol withdrawal.

Long-Term Evidence and Areas for Further Research

The majority of reported studies was observed in short-term research scenarios, meaning follow-up durations were limited, typically lasting only a few weeks. Because of this, long-term effects are not fully established, and there is limited information for long-term outcomes regarding the durability of patient responses. The overall evidence landscape is limited by a modest volume of modern trials, and data for certain groups remain insufficient, meaning results are applicable only to the populations studied. Research highlights what is known — and what is still uncertain. Findings describe group patterns, not personal outcomes.

Key Studies & References

1. A Comparison of the Anxiolytic Properties of Tofisopam and Diazepam: A Double-Blind, Randomized, Crossover, Placebo-Controlled Pilot Study
2. A review of the evidence of use and harms of Novel Benzodiazepines (ACMD Report)

Common questions about No Deprine (FAQ)

---

Q: Is No Deprine the same as other depression medicines?

A: No Deprine is officially classified as an anxiolytic, a type of medicine intended to help reduce anxiety and manage physical symptoms of nervous tension. Official documents indicate it is chemically and functionally distinct from many common antidepressants. Regulatory guidelines note it is not recommended for use as the only treatment (monotherapy) for depression.

Q: How quickly does No Deprine start to work?

A: Regulatory documents state that No Deprine is absorbed rapidly after being taken orally. The time it takes for the medicine to reach its maximum concentration in the blood is about two hours after administration. This pharmacokinetic information describes how the medicine is processed by the body.

Q: What is the typical timeframe before noticing the effects of No Deprine?

A: Studies show the drug reaches its peak concentration in the blood approximately two hours after taking a dose. While the onset of clinical effects can vary among individuals, the medicine is officially described as a non-sedating, daytime anxiolytic. Its functional activity is generally associated with waking hours.

Q: Is it common to feel tired when first starting No Deprine?

A: Official product information frequently highlights that No Deprine does not cause the sedative effects associated with certain other medicines in this class. In fact, possible side effects listed in regulatory documents include the opposite, such as insomnia (difficulty sleeping) and a feeling of agitation or irritability. Patients who experience unusual effects should consult their healthcare provider.

Q: Does No Deprine interact with common pain relievers?

A: The official interaction profile focuses on medicines that affect the central nervous system (CNS depressants) and drugs processed by a specific liver enzyme called CYP3A4. While common over-the-counter pain relievers are not explicitly named in the warnings, it is important that patients review all medications, including pain relievers, with a healthcare professional to assess the risk of potential interactions.

Q: What foods or drinks should be used with caution while taking No Deprine?

A: Official information advises that the consumption of alcohol should be avoided while using this medicine, as there is a risk of enhanced effects on the central nervous system. Additionally, official regulatory sheets also advise caution regarding the consumption of beverages that contain caffeine.

Q: Is No Deprine habit-forming or addictive?

A: Official warnings note the formal safety consideration of potential tolerance and dependence, especially when the medicine is used for extended periods. Regulatory bodies recommend that the medicine be used strictly according to the dose and duration prescribed.

Q: Can I stop taking No Deprine when I feel better?

A: Official guidance states that abruptly stopping the use of this medicine can lead to significant withdrawal symptoms. This is why any decision to change the dose or discontinue treatment should be guided by a healthcare professional.

Q: Are there different strengths or forms of No Deprine available?

A: The core form described in regulatory documents is the 50 mg tablet. Official product information does not widely list other specific strengths or alternative formulations, such as extended-release capsules. The approved form is a solid oral tablet.

Q: Is there a generic version of No Deprine?

A: Yes, the active ingredient in No Deprine, Tofisopam, is available in both the original brand name and several generic formulations, depending on the country. Generic formulations contain the exact same active ingredient but may have different brand names from the original manufacturer.

Q: Are there any known interactions between No Deprine and supplements?

A: Official documentation indicates that No Deprine may interact with multivitamin, multi-mineral, or other herbal supplements. Official documentation indicates the importance of informing a healthcare professional about all over-the-counter products and supplements being used.

Q: Can No Deprine cause problems with concentration?

A: Official regulatory information typically notes that the medicine does not impair cognitive abilities or psychomotor performance, meaning it usually does not directly affect concentration. However, certain listed side effects, such as insomnia or confusion, could potentially affect a person's focus.

Q: Do studies show No Deprine works for mild symptoms?

A: Official documents describe the medicine's indications for use as including anxiety and psychovegetative symptoms. Furthermore, it is specifically indicated for use in the management of symptoms associated with mild Alcohol Withdrawal Syndrome. This shows its use in conditions where symptoms may be less severe.

Q: Is No Deprine used for conditions other than depression?

A: Yes, No Deprine is indicated for treating a range of symptoms beyond those related to depression. According to official documents, this includes symptoms associated with autonomic imbalance, various anxiety disorders, and the management of symptoms during mild alcohol withdrawal syndrome.

Q: Does No Deprine require any special lab tests while using it?

A: Due to official warnings regarding potential serious adverse effects like Cholestatic jaundice, monitoring of organ function, such as liver function, may be necessary for risk management. This caution is heightened for patients with existing liver or kidney disease.

Q: Why do some people experience initial anxiety when starting No Deprine?

A: Official safety documents note that in some cases, patients may experience what are called paradoxical reactions when first starting the medicine. These reactions can include feelings of increased irritability or agitation, which are the opposite of the intended calming effect. This reaction is generally associated with the initial phase of treatment.

Q: Does No Deprine cause dry mouth?

A: Yes, dry mouth is listed in official documentation as a commonly reported adverse reaction. This is generally grouped with other gastrointestinal or digestive system side effects.

Q: What is the typical duration of treatment with No Deprine?

A: Official guidance often recommends that the medicine be prescribed for a maximum duration of twelve weeks. Furthermore, for specific conditions like mild alcohol withdrawal syndrome, a short course of therapy is often indicated.

Q: Can No Deprine affect blood pressure?

A: While it is not typically listed as a common side effect at standard doses, official documents indicate that very low blood pressure (hypotension) is a potential complication. This is particularly noted in cases of medicine overdose or severe toxicity.

Q: Does No Deprine have a 'black box' warning?

A: The specific US term 'Black Box Warning' is not universally applied across all international regulatory documents for this medicine. However, official safety profiles do include formal warnings for serious but rare adverse reactions, such as Cholestatic jaundice and respiratory depression, as well as cautions regarding tolerance and dependence.

Q: How are the clinical trials for No Deprine described in official documents?

A: The studies supporting the use of No Deprine are officially described as being randomized controlled trials, with some comparing the drug to a non-active placebo or other anxiolytics. These studies primarily focused on short-term outcomes related to anxiety symptoms and psychomotor performance.

Q: Does No Deprine interact with birth control pills?

A: No Deprine is officially documented as an inhibitor of the CYP3A4 liver enzyme. Because hormonal contraceptives (birth control pills) are often processed by this same enzyme, taking No Deprine simultaneously may theoretically reduce the effectiveness of the birth control pills. Patients using hormonal contraceptives should consult their physician regarding this potential interaction.

Official Storage and Disposal Requirements

No Deprine (Tofisopam) must be stored under controlled conditions to protect its integrity. Regulatory documents require the product be kept in a cool, dry place, protected from moisture and stored away from direct sunlight to prevent degradation. The container should be kept tightly closed.

All medicine must be stored out of the reach of children.

Disposal must be conducted strictly in accordance with local and national regulations. Due to the compound's classification as very toxic to aquatic life, unused or expired medication must not be discharged into drains or water courses. Disposal should be entrusted to a licensed waste facility, and the product must not be used past its expiry date.